Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

Mertz, Shirley; Benjamin, Christine; Girvalaki, Charis; Cardone, Antonella; Gono, Paulina; May, Suepattra G.; Comerford, Erin; Than, Kyi-Sin; Birch, Kelly; Roach, Meaghan; Myers, Sky; Sasané, Medha; Lavi, Liat; Cameron, A. T.; Cardoso, Fátima

doi:10.1016/j.breast.2022.07.006

Cited by 14 publications

(18 citation statements)

References 42 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detailed screening of titles and abstracts for potential eligibility was performed, 1357 were duplicated, and the irrelevant papers were removed. According to inclusion and exclusion criteria, the full texts of 27 articles were reviewed and 19 articles were subsequently excluded and finally, 9 full papers [11][12][13][14][15][16][17][18][19][20] were retrieved for detailed examination. In further assessment, one article 12 was omitted because it was evaluated in the last systematic review by Devi et al 9 (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…Also, they believe that improved QoL is important that may vary by age, duration of illness, and treatment modalities. 20 Physical Effects. Physical QoL and activity was severely diminished by symptoms such as severe pain, nausea, gastrointestinal discomfort, flu-like symptoms, cardiovascular dysfunction, edema, stomatitis, neuropathies, muscles and joints stiffness, dyspnea, dizziness, sleep problems, hair loss and menopausal symptoms.…”

Section: Resultsmentioning

confidence: 99%

“…Also, they believe that improved QoL is important that may vary by age, duration of illness, and treatment modalities. 20…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies

et al. 2023

View full text Add to dashboard Cite

Objective Quality of life (QoL) in breast cancer patients is still an important topic. Despite numerous quantitative scales, qualitative studies can help to in-depth understand the QoL of breast cancer patients. The purpose of this systematic review was to integrate qualitative studies on the QoL of women with breast cancer. Methods A literature search was performed in electronic databases including PubMed, Scopus, and Web of Science from January 1, 2010 until June 28, 2022 to find out qualitative studies assessing breast cancer patient’s QoL. Two authors independently evaluated methodological quality according to the consolidated criteria for reporting qualitative research (COREQ) checklist. Data were extracted and reported by themes for cancer-free women and patients with metastatic cancer separately. Results In all, 1565 citations were retrieved. After removing 1387 duplicate and irrelevant papers, the full texts of 27 articles were reviewed and finally, 9 were eligible for evaluation. In quality checking of the citations, all articles gained the required quality score. After examining and merging similar topics, nine major themes were extracted. Physical, spiritual, and psychological aspects of QoL were the common issues in cancer-free women (before and after the COVID-19 pandemic) and patients with metastatic cancer. Perception of cancer and social life were the other main concerns in cancer-free women, whereas, in metastatic patients’ overall survival and planning for the future and their children’s life was the focus of interest. Women with metastatic disease showed more vulnerability in coping compared to cancer-free women. Conclusion This review provides an opportunity to have a closer look into the several domains of QoL in women with breast cancer. In-depth information provided by this review might help to develop interventions for patients and their families to support women to cope much better with their life challenges.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…As a result, the importance of endpoints is changing and PFS is attaining a higher status (Staab et al 2016 ). From the patient´s perspective, other endpoints also appear to be gaining in importance; for example, an analysis from 2022 highlights that patients with mBC consider OS to be the most important primary endpoint, but that PFS is also of crucial importance and must therefore be taken into account in medical evaluation procedures as well (Mertz et al 2022 ). The differences in results between the institutions are clearer when comparing the European level and the German level (ESMO vs. GBA) than within Germany (DGHO vs. GBA): 67% of the assessments of the Top 4 drugs by the ESMO differ from the additional benefit assessment by the GBA, whereas only 43% of the assessments of the Top 4 drugs by the DGHO differ from the additional benefit assessments by the GBA.…”

Section: Discussionmentioning

confidence: 99%

Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany

Obst

Seifert

2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The prices of oncology drugs have been rising progressively in recent years. Despite accounting for only a small share of prescriptions, oncology drugs are the most expensive drugs on the market. However, the association between drug price and clinical benefit often remains questionable. Therefore, we set out to analyze the development of prescription and benefit assessment of protein kinase inhibitors. We identified 20 protein kinase inhibitors with oncological indications that were newly approved by the European Medicines Agency (EMA) between 2015 and 2019, based on the Arzneiverordnungsreport (AVR, Drug Prescription Report). For these 20 drugs, the number of prescriptions, sales, defined daily dose (DDD), and DDD costs were identified for the year of approval and for 2020, respectively, based on data from the Wissenschaftliches Institut der Ortskrankenkassen (WIdO, Scientific Institute of the General Local Health Insurance Fund, AOK). Moreover, the additional benefit assessments by the Gemeinsamer Bundesausschuss (GBA, Federal Joint Committee) were considered for each drug. It is shown that the share of a drug in prescriptions, sales, and DDD does not correlate with the clinical benefit of the drug as measured by the additional benefit assessment by the GBA. Lastly, the advertisement pattern of protein kinase inhibitors in a representative oncology journal does not correlate with drug benefit. In conclusion, the immense costs of oncology drugs are therefore largely caused by drugs for which no additional benefit has been proven by the GBA. In order to ensure the long-term stability of health care systems, price-regulation measures are urgently needed, especially for drugs whose additional benefit has not been proven.

show abstract

“…The development of new treatments unavoidably led to different toxicity profiles, which means that there is a true need of an organized network of professional healthcare figures involved in the patients’ treatment path. Moreover, improved survival outcomes recently translated into particular attention for quality of life (QoL) [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients

Fabi,

Rossi,

Mocini

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Background Breast cancer (BC) treatment has recently been revolutionized by the introduction of newer targeted agents, that helped tailoring therapies around the single patient. Along with increased survival rates, a careful evaluation of diet, lifestyle habits, physical activity, emotional and psychological experiences linked to the treatment journey, is now mandatory. However, a true proposal for an omnicomprehensive and “integrative” approach is still lacking in literature. Methods A scientific board of internationally recognized specialists throughout different disciplines designed a shared proposal of holistic approach for BC patients. Results A narrative review, containing information on BC treatment, endocrinological and diet aspects, physical activity, rehabilitation, integrative medicine, and digital narrative medicine, was developed. Conclusions In the context of a patient-centered care, BC treatment cannot be separated from a patient’s long-term follow-up and care, and an organized interdisciplinary collaboration is the future in this disease’s cure, to make sure that our patients will live longer and better. Trial Registration NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (PERGIQUAL). Registration date: 29th May 2023.

show abstract

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

Cited by 14 publications

References 42 publications

Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies

Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies

Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany

An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients

Contact Info

Product

Resources

About